ADCT (ADC Therapeutics) Float Percentage Of Total Shares Outstanding : 78.60% (As of Jul. 05, 2025)

View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ADC Therapeutics's float shares is 78.00 Mil. ADC Therapeutics's total shares outstanding is 99.23 Mil. ADC Therapeutics's float percentage of total shares outstanding is 78.60%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ADC Therapeutics's Insider Ownership is 4.04%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ADC Therapeutics's Institutional Ownership is 56.20%.

ADC Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

ADC Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	78.00	/	99.23
	=	78.60%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADC Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066

Website

https://www.adctherapeutics.com

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).